US EditionDELFI Diagnostics CTO Recognized among 2025 Most Influential Women in Bay Area Business
- On May 12, 2025, Dr. Amoolya Singh, Chief Technology Officer of DELFI Diagnostics, was recognized by the San Francisco Business Times as one of the top women leaders shaping the Bay Area's business community.
- She became a member of DELFI Diagnostics in December 2024, bringing more than 20 years of expertise in biotechnology and computational science, and was recognized as one of the top leaders among several hundred candidates.
- Dr. Singh leads DELFI's strategic technology roadmap to develop reliable, affordable, non-invasive blood tests using cell-free DNA fragmentomics for early cancer detection and monitoring.
- DELFI's clinically validated FirstLook Lung test uses machine learning on cfDNA fragments, achieves a 99.8% negative predictive value, and aims to improve lung cancer detection for eligible individuals through a simple blood draw.
- This recognition highlights Dr. Singh's role in advancing AI-driven cancer screening to benefit high-risk and underserved populations and underscores DELFI's mission to transform cancer diagnosis globally.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
1
Center
8
Right
Coverage Details
Total News Sources20
Leaning Left1Leaning Right0Center8Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
11%
C 89%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
